What does triple-negative breast cancer (TNBC) mean?

What Triple-Negative Breast Cancer Means

Triple-negative breast cancer (TNBC) is a breast cancer subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and lack of HER2 overexpression/amplification 1.

Definition and Molecular Characteristics

TNBC is characterized by:

• Negative for ER expression
• Negative for PR expression
• Negative for HER2 overexpression (no amplification of the HER2 gene)

This triple-negative status means the tumor lacks the three most common therapeutic targets in breast cancer, making hormone therapy and HER2-targeted treatments ineffective 1, 2.

Epidemiology and Prevalence

TNBC accounts for 10-20% of all invasive breast cancers 1. Key epidemiological features include:

• Three times more common in women of African descent compared to other racial groups 1
• More prevalent in premenopausal women (39% in premenopausal African-American women versus 14% in postmenopausal) 1
• Associated with younger age at diagnosis 1
• Strong association with BRCA1 mutations and family history of breast cancer 1
• Linked to socioeconomic deprivation status 1

Clinical Behavior and Prognosis

TNBC carries a relatively poorer prognosis than other major breast cancer subtypes 1. Critical prognostic features include:

• Peak risk of recurrence within 3 years of diagnosis 1
• Increased mortality rates for 5 years after diagnosis 1
• More advanced disease stage at presentation 1
• Higher tumor grade with high mitotic indices 1
• More marked nuclear pleomorphism 1
• Rapid metastatic progression 3

Relationship to Basal-Like Breast Cancer

While approximately 75% of TNBC cases are basal-like breast cancer, the terms are not interchangeable 1. TNBC is frequently but erroneously used as a surrogate marker for basal-like subtype 1. The basal-like subtype is defined by additional markers (cytokeratin 5/6 positive and/or epidermal growth factor receptor positive) beyond the triple-negative status 1.

Biological Heterogeneity

TNBC exhibits severe biological heterogeneity at histopathological, proteomic, transcriptomic, and genomic levels 4. This diversity creates multiple molecular subtypes within TNBC, each with distinct pathological behavior and treatment responses 4. This heterogeneity is a major factor contributing to treatment challenges and the need for personalized approaches 5.

Treatment Implications

The absence of ER, PR, and HER2 expression means:

• Standard hormone therapies are ineffective 2
• HER2-targeted therapies cannot be used 2
• Chemotherapy remains the mainstay of treatment 5
• Newer options include immunotherapy (for PD-L1 positive tumors), PARP inhibitors (for BRCA-mutated cases), and antibody-drug conjugates 2, 5